Dalpiciclib

Generic Name: Dalpiciclib

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₀N_₆O_₂

CAS Number: 1637781-04-4

Unique Ingredient Identifier: 5ZHA5P4PFX

Clinical Trials

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Not Applicable

Not yet recruiting

Conditions: HR+/HER2- Advanced Breast Cancer

Interventions: Drug: Dalpiciclib

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: Fujian Medical University

Target Recruit Count: 52

Registration Number: NCT06711094

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Dalpiciclib + Pyrotinib

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-12

Lead Sponsor: Peking University

Target Recruit Count: 35

Registration Number: NCT06684600

Locations: 🇨🇳
Department of GI Oncology, Peking University Cancer Hospital,, Beijing, Beijing, China

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Letrozole

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-26

Lead Sponsor: Peking University

Target Recruit Count: 100

Registration Number: NCT06650748

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

Phase 4

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Jiangsu Famous Medical Technology Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT06613373

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer Metastatic

Interventions: Drug: Fluzoparib
Drug: Dalpiciclib
Drug: Fulvestrant/AI

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Zhimin Shao

Target Recruit Count: 307

Registration Number: NCT06612814

Locations: 🇨🇳
breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

Not Applicable

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib and Letrozole Combined With Anlotinib

First Posted Date: 2024-09-20

Last Posted Date: 2024-09-20

Lead Sponsor: Liu Shu

Target Recruit Count: 30

Registration Number: NCT06605690

Exploration of Dalpiciclib + Tucidinostat in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Phase 2

Not yet recruiting

Conditions: HR+/HER2- Advanced Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Tucidinostat

First Posted Date: 2024-08-16

Last Posted Date: 2024-08-16

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 155

Registration Number: NCT06556862

Locations: 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Fluzoparib
Drug: Dalpiciclib

First Posted Date: 2024-08-14

Last Posted Date: 2024-08-14

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT06552858

Locations: 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Phase 2

Recruiting

Conditions: Early Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Endocrine therapy

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-02

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 1163

Registration Number: NCT06341894

Locations: 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Dalpiciclib in HR+/HER2- ABC

Not yet recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: dalpiciclib

First Posted Date: 2024-03-08

Last Posted Date: 2024-04-16

Lead Sponsor: RenJi Hospital

Target Recruit Count: 103

Registration Number: NCT06301438

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy